What is the significance of a ferritin level of 448 ng/mL and how should it be evaluated and managed?

Evaluation and Management of Ferritin 448 ng/mL

A ferritin of 448 ng/mL is moderately elevated and requires immediate measurement of transferrin saturation (TSAT) to determine if this represents true iron overload versus an inflammatory/secondary cause. 1

Initial Diagnostic Approach

The key distinguishing test is transferrin saturation, which determines your next steps:

• If TSAT ≥ 45%: This suggests true iron overload and mandates HFE genetic testing (C282Y and H63D mutations) to evaluate for hereditary hemochromatosis 1
• If TSAT < 45%: The elevated ferritin is more likely due to inflammation, liver disease, metabolic syndrome, or malignancy rather than iron overload 1, 2

Critical Context for Interpretation

Ferritin is an acute phase reactant with significant false-positive rates. It elevates in multiple non-iron-overload conditions 1:

• Necroinflammatory liver disease (hepatitis B/C, NAFLD, alcoholic liver disease)
• Chronic inflammatory conditions
• Malignancy (particularly lymphomas)
• Metabolic syndrome

In the general population, iron overload is NOT the most common cause of elevated ferritin 1. This is why TSAT is essential—it has less biological variability and better specificity for iron overload.

Risk Stratification Based on Ferritin Level

At 448 ng/mL, this patient falls into an intermediate-risk category:

• Ferritin <1000 ng/mL with normal liver enzymes: Low risk for cirrhosis; if C282Y homozygote confirmed, can proceed directly to phlebotomy without liver biopsy 1
• Ferritin >1000 ng/mL: Higher risk requiring more extensive evaluation including consideration of liver biopsy 1

Studies demonstrate that ferritin >1000 ng/mL combined with elevated ALT/AST and platelets <200 predicts cirrhosis in 80% of C282Y homozygotes 1. Your patient at 448 ng/mL is below this threshold.

Management Algorithm

If Hereditary Hemochromatosis is Confirmed (C282Y homozygote):

Initiate therapeutic phlebotomy immediately:

• Remove 400-500 mL weekly or every 2 weeks during induction phase 3, 1
• Check hemoglobin before each session; discontinue if Hgb <11 g/dL 3
• Monitor ferritin every 10-12 phlebotomies (or monthly) 3, 1
• Target ferritin: 50-100 ng/mL 1

Once target achieved, transition to maintenance phlebotomy every 1-4 months to keep ferritin 50-100 ng/mL 3, 1.

Dietary Modifications (Weak Evidence):

• Avoid iron supplements and iron-fortified foods 3, 1
• Avoid supplemental vitamin C, especially before iron depletion 3, 1
• Limit red meat consumption 3
• Restrict alcohol during iron depletion phase 3
• Avoid raw or undercooked shellfish (risk of Vibrio vulnificus infection in iron overload) 1

If Non-HFE or Secondary Iron Overload:

Evaluate for underlying causes:

• Liver disease markers (ALT, AST, hepatitis serologies)
• Inflammatory markers (CRP, ESR)
• Metabolic syndrome components (glucose, lipids, BMI)
• Malignancy screening if clinically indicated

Common Pitfalls to Avoid

1. Do not assume elevated ferritin equals iron overload without checking TSAT 1, 2
2. Do not order liver biopsy in C282Y homozygotes with ferritin <1000 ng/mL and normal liver enzymes—proceed directly to phlebotomy 1
3. Do not over-treat with phlebotomy—target ferritin 50-100 ng/mL, not lower, to avoid iron deficiency 3, 1
4. Fasting samples are no longer required for TSAT measurement, though confirming an elevated TSAT with a second determination is reasonable 1

Monitoring Strategy

• During induction: Hemoglobin before each phlebotomy; ferritin monthly or every 4th session 3
• When ferritin drops below 200 ng/mL: Check ferritin every 1-2 sessions 3
• During maintenance: Ferritin every 6 months 3
• Consider periodic folate and B12 monitoring in patients requiring numerous venesections 3

The 2022 EASL guidelines 3 and 2011 AASLD guidelines 1 provide the strongest evidence base for this approach, with consistent recommendations across both.